Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

JYH-MING LIOUYU-JEN FANGCHIEH-CHANG CHENBair, Ming-JongMing-JongBairChang, Chi-YangChi-YangChangYI-CHIA LEEMEI-JYH CHENCHIEN-CHUAN CHENTseng, Cheng-HaoCheng-HaoTsengHsu, Yao-ChunYao-ChunHsuLee, Ji-YuhJi-YuhLeeYang, Tsung-HuaTsung-HuaYangLuo, Jiing-ChyuanJiing-ChyuanLuoChang, Chun-ChaoChun-ChaoChangChen, Chi-YiChi-YiChenChen, Po-YuehPo-YuehChenCHIA-TUNG SHUNWEN-FENG HSUWEN-HAO HUYEN-NIEN CHENSheu, Bor-ShyangBor-ShyangSheuLin, Jaw-TownJaw-TownLinWu, Jeng-YihJeng-YihWuEl-Omar, Emad MEmad MEl-OmarMING-SHIANG WU2023-06-132023-06-132016-11-120140-6736https://scholars.lib.ntu.edu.tw/handle/123456789/632669Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori.enGASTRIC-CANCER; SEQUENTIAL THERAPY; INFECTION; ERADICATION; METAANALYSIS; CLARITHROMYCIN; RESISTANCE; EFFICACY; METRONIDAZOLE; ESOMEPRAZOLEConcomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialjournal article10.1016/S0140-6736(16)31409-X277695622-s2.0-84994756793WOS:000387436900024https://scholars.lib.ntu.edu.tw/handle/123456789/553126